Outlook Therapeutics (OTLK) vs Atrium Therapeutics (RNA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atrium Therapeutics is the larger company by market cap ($141.3 million vs $137.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OTLK | RNA |
|---|---|---|
| Share price | $0.564 | $8.26 |
| Market cap | $137.30M | $141.29M |
| 1-day change | -4.41% | +4.16% |
| YTD return | -64.30% | — |
| 1-year return | -55.24% | — |
| 5-year return | -98.66% | — |
| EPS (TTM) | $-0.70 | $-5.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.54 | $16.77 |
| 52-week low | $0.161 | $7.63 |
| Distance from 52-week high | -77.78% | -50.75% |
| Analyst consensus | none | none |
| Avg. price target upside | +791.84% | +202.66% |
| Average volume | 13.33M | 259.35K |
| Shares outstanding | 243.45M | 17.11M |
| Employees | 17 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Outlook Therapeutics
OTLK stock →Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 17 employees
About Atrium Therapeutics
RNA stock →Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy.
Health Care · Biotechnology: Pharmaceutical Preparations
OTLK vs RNA FAQ
Which is bigger, Outlook Therapeutics or Atrium Therapeutics?
Atrium Therapeutics (RNA) is larger, with a market capitalization of $141.29M compared with $137.30M for Outlook Therapeutics (OTLK).
Are Outlook Therapeutics and Atrium Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Outlook Therapeutics and Biotechnology: Pharmaceutical Preparations for Atrium Therapeutics.